NeOnc Technologies 3Q 2026: Revenue $0, EPS ($0.28) — 10-Q Summary
NeOnc Technologies reported no revenue and a net loss of $0.28 per share in 3Q 2026, with reduced stock-based compensation and debt costs offset by higher R&D and legal expenses. Clinical trials NEO100-01, NEO100-02, and NEO212 showed progress, with R&D expenses rising to $1.3M.
How this was made
The 30-second read
Why it matters
The results underscore ongoing development costs and limited commercial traction, likely weighing on the stock.
Market read
Micro‑cap biotech investors will reassess exposure; the stock may face short‑term downside.
What to watch
Potential upside from upcoming Phase 2 trial designs and the Series A derivative gain.
Background
NeOnc Technologies Holdings, Inc. filed its Form 10‑Q for Q3 2026, disclosing zero revenue and a narrowed loss per share.
Ticker impact
10-Q reports Q3 2026 revenue of $0 and a narrowed net loss per share of ($0.28).
likely pressure as the market prices in the revenue miss and loss.
Quarterly results are the first public disclosure of these numbers; investors typically react negatively to zero revenue and a loss.
Market effects
Biotech micro‑cap sector may see broader risk‑off sentiment after another zero‑revenue report.
U.S. small‑cap biotech indices could dip modestly.
Limited; impact confined to niche biotech investors.
Counterpoint
If the clinical trial data (NEO100‑01 Phase 2a) shows strong efficacy, the stock could rebound on future milestones.
Key entities
- CompanyNeOnc Technologies Holdings, Inc.
Biotech firm developing NEO100 and NEO212 oncology candidates.
